Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722877 | 0.81 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6722092 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL7046192 | 0.81 | PTGS2 (0.49) | PTGS2PTGS1PDE3BPDE3AALOX5AP | |
| SCHEMBL6722728 | 0.81 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL6725527 | 0.81 | PTGS2 (0.45) | PTGS2PTGER1PTGS1PDE3BPDE3A | |
| SCHEMBL6721827 | 0.81 | PDE3B (0.41) | PTGS2PTGS1PDE3BPDE3AALOX5AP | |
| SCHEMBL6721801 | 0.80 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6718983 | 0.80 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6718366 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL6721860 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1PDE3BPDE3AALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGER1 18/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.